MY136210A - Purified immunoglobulin - Google Patents

Purified immunoglobulin

Info

Publication number
MY136210A
MY136210A MYPI92001385A MYPI9201385A MY136210A MY 136210 A MY136210 A MY 136210A MY PI92001385 A MYPI92001385 A MY PI92001385A MY PI9201385 A MYPI9201385 A MY PI9201385A MY 136210 A MY136210 A MY 136210A
Authority
MY
Malaysia
Prior art keywords
reducing conditions
recombinant antibody
purified preparation
major peaks
reduced sample
Prior art date
Application number
MYPI92001385A
Other languages
English (en)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY136210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MY136210A publication Critical patent/MY136210A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI92001385A 1990-10-17 1991-10-16 Purified immunoglobulin MY136210A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (1)

Publication Number Publication Date
MY136210A true MY136210A (en) 2008-08-29

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI92001385A MY136210A (en) 1990-10-17 1991-10-16 Purified immunoglobulin
MYPI91001909A MY119030A (en) 1990-10-17 1991-10-16 Purified immunoglobulin

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI91001909A MY119030A (en) 1990-10-17 1991-10-16 Purified immunoglobulin

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATA900791A (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681455A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2112865T5 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL99761A0 (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY136210A (enExample)
NZ (2) NZ240247A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA926191B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
MY115415A (en) * 1991-10-15 2003-06-30 Wellcome Found Medicaments.
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
EP0841942B2 (fr) † 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP1380589A4 (en) 2001-03-09 2004-09-01 Chugai Pharmaceutical Co Ltd PROTEIN CLEANING METHOD
DE60213248T2 (de) * 2001-06-05 2006-11-30 Genetics Institute, LLC, Cambridge Verfahren zur reinigung hochanionischer proteine
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
US8420789B2 (en) 2002-09-11 2013-04-16 Chugai Seiyaku Kabushiki Kaisha Method for removing DNA contaminants from a protein-containing sample
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
KR101537840B1 (ko) 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
EP3345620B1 (en) 2009-05-13 2024-08-28 Genzyme Corporation Methods and compositions for treating lupus
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
US20130096284A1 (en) 2010-06-21 2013-04-18 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2714967C2 (ru) 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
WO2017022651A1 (ja) 2015-07-31 2017-02-09 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
ES2994244T3 (en) 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
WO2020203718A1 (ja) 2019-03-29 2020-10-08 旭化成メディカル株式会社 タンパク質の精製方法
US12383884B2 (en) 2019-04-08 2025-08-12 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
TW202104244A (zh) 2019-04-10 2021-02-01 日商中外製藥股份有限公司 Fc區域改變抗體的純化方法
CN117241881A (zh) 2021-06-10 2023-12-15 三菱化学株式会社 合成吸附剂、抗体的纯化方法和抗体的制造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
DE10199051I2 (de) * 1988-02-12 2005-05-04 Btg Int Ltd Modifizierte Antik¦rper.

Also Published As

Publication number Publication date
CH681305A5 (enExample) 1993-02-26
DK0504363T3 (da) 1998-09-21
FI922824L (fi) 1992-06-17
PT99248B (pt) 1999-04-30
AU4521897A (en) 1998-02-12
GR910100425A (el) 1992-09-25
IL102726A (en) 2002-08-14
ZA926191B (en) 1993-04-16
AU658926B2 (en) 1995-05-04
FI110002B (fi) 2002-11-15
IT1250064B (it) 1995-03-30
JP2638680B2 (ja) 1997-08-06
DE69128774T2 (de) 1998-06-04
KR920703108A (ko) 1992-12-17
US5644036A (en) 1997-07-01
IE913560A1 (en) 1992-04-22
FI922380L (fi) 1992-05-25
CA2069481C (en) 2003-07-29
EP0504363A1 (en) 1992-09-23
IL102726A0 (en) 1993-01-31
IL99761A0 (en) 1992-08-18
DE69128774D1 (de) 1998-02-26
HU9202000D0 (en) 1992-10-28
GB2253397A (en) 1992-09-09
GR920100471A (el) 1994-06-30
BE1004226A5 (fr) 1992-10-13
AU7024294A (en) 1995-01-05
TW283710B (enExample) 1996-08-21
WO1992007084A1 (en) 1992-04-30
FI922824A0 (fi) 1992-06-17
ITRM910788A0 (it) 1991-10-16
DK0504363T4 (da) 2007-05-29
AU716402B2 (en) 2000-02-24
ES2081742A1 (es) 1996-03-01
HUT64601A (en) 1994-01-28
FR2668164A1 (fr) 1992-04-24
FI110003B (fi) 2002-11-15
NZ244114A (en) 1995-06-27
GB9209529D0 (en) 1992-07-01
FR2677997A1 (fr) 1992-12-24
MY119030A (en) 2005-03-31
FI922380A0 (fi) 1992-05-25
ES2112865T5 (es) 2007-09-16
KR100193314B1 (ko) 1999-06-15
ITRM910788A1 (it) 1993-04-16
ES2081742B1 (es) 1996-10-01
FR2668164B1 (enExample) 1995-04-14
KR960015399B1 (ko) 1996-11-13
CA2069481A1 (en) 1992-04-18
PT99248A (pt) 1993-06-30
ATE162552T1 (de) 1998-02-15
NZ240247A (en) 1994-03-25
ES2112865T3 (es) 1998-04-16
DE69128774T3 (de) 2007-08-16
GR3026588T3 (en) 1998-07-31
GB9022547D0 (en) 1990-11-28
BR1100358A (pt) 2000-03-28
PT100988A (pt) 1994-02-28
JPH05504579A (ja) 1993-07-15
PT100988B (pt) 1999-08-31
EP0504363B2 (en) 2007-02-07
LU88122A1 (fr) 1993-03-15
AU8729491A (en) 1992-05-20
ZA918259B (en) 1993-04-16
CH681455A5 (enExample) 1993-03-31
MX9203794A (es) 1992-07-01
ATA900791A (de) 1996-06-15
AU2532192A (en) 1993-02-11
AU649078B2 (en) 1994-05-12
EP0504363B1 (en) 1998-01-21

Similar Documents

Publication Publication Date Title
MY136210A (en) Purified immunoglobulin
AU5191186A (en) Method for the purification of erythroppietin and erythropoietin compositions
ZA944950B (en) Protein purification
AU2671795A (en) Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
IL69731A0 (en) Homogeneous human interleukin 2,its preparation and pharmaceutical compositions containing it
CA2081150A1 (en) Use of antibody-containing preparations for immunosuppression
IE801137L (en) Dna transfer vector
PL346865A1 (en) Method for chromatographically purifying insulins
ES489521A0 (es) Un procedimiento para la preparacion de un peptido
AU2629792A (en) Process for the purification of streptolysin 0, intact streptolysin 0 obtained by this process and its use
IL110227A0 (en) Difluoro statone analogs
IT1247534B (it) Anticorpo nl07 e relativo procedimento di produzione
IT1157502B (it) Antenna televisiva premontata, di ingombro riducibile e di rapido adattamento all'impiego
IT8206908V0 (it) Antenna televisiva premontata, di ingombro riducibile e di rapido adattamento all'impiego.